Apellis Pharmaceuticals (APLS) Financials

$17.42 -1.09 (-5.89%)

Closing price 04:00 PM Eastern

Extended Trading

$17.42 0.00 (0.00%)

As of 05:07 PM Eastern

Annual Income Statements for Apellis Pharmaceuticals

This table shows Apellis Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-198	-529	-651	-748	-345	-305	-128	-51	-27	-47
Consolidated Net Income / (Loss)	-198	-529	-652	-746	-345	-305	-128	-51	-27	-47
Net Income / (Loss) Continuing Operations	-198	-529	-652	-746	-345	-305	-128	-51	-27	-47
Total Pre-Tax Income	-197	-526	-652	-746	-343	-305	-128	-51	-27	-47
Total Operating Income	-165	-517	-595	-536	-214	-288	-128	-51	-27	-47
Total Gross Profit	781	397	75	67	251	0.00	0.00	0.00	0.00	0.00
Total Revenue	781	397	75	67	251	0.00	0.00	0.00	0.00	0.00
Operating Revenue	781	397	75	67	251	0.00	0.00	-	-	-
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	946	914	670	603	464	288	128	51	27	47
Selling, General & Admin Expense	501	501	277	177	139	67	23	10	4.30	6.36
Research & Development Expense	328	354	387	346	300	221	105	40	23	40
Other Operating Expenses / (Income)	118	59	0.00	75	25	0.00	-	-	-	-
Total Other Income / (Expense), net	-32	-9.38	-57	-210	-129	-17	0.42	-0.24	0.16	0.06
Interest Expense	40	30	33	13	30	6.79	2.51	0.37	0.00	-
Interest & Investment Income	13	21	8.91	0.42	4.16	5.11	2.96	0.28	0.14	0.05
Other Income / (Expense), net	-4.12	-0.73	-33	-197	-104	-15	-0.03	-0.14	0.02	0.01
Income Tax Expense	1.16	2.13	0.67	0.35	1.85	0.00	0.00	-	-	-
Basic Earnings per Share	($1.60)	($4.45)	($6.15)	($8.84)	($4.59)	($4.90)	($2.34)	($3.68)	($3.22)	($8.03)
Weighted Average Basic Shares Outstanding	123.91M	118.68M	106.11M	84.42M	75.16M	62.23M	54.40M	13.87M	8.43M	5.80M
Diluted Earnings per Share	($1.60)	($4.45)	($6.15)	($8.84)	($4.59)	($4.90)	($2.34)	($3.68)	($3.22)	($8.03)
Weighted Average Diluted Shares Outstanding	123.91M	118.68M	106.11M	84.42M	75.16M	62.23M	54.40M	13.87M	8.43M	5.80M
Weighted Average Basic & Diluted Shares Outstanding	125.52M	120.58M	111.29M	84.42M	75.16M	62.23M	54.40M	13.87M	8.43M	5.80M

This table shows Apellis Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-92	-36	-57	-38	-66	-89	-140	-122	-178	-164	-191
Consolidated Net Income / (Loss)	-92	-36	-57	-38	-66	-89	-140	-122	-178	-166	-191
Net Income / (Loss) Continuing Operations	-92	-36	-57	-38	-66	-89	-140	-122	-178	-166	-191
Total Pre-Tax Income	-92	-36	-57	-38	-66	-87	-140	-122	-177	-167	-191
Total Operating Income	-83	-26	-47	-29	-62	-85	-137	-120	-175	-164	-153
Total Gross Profit	167	213	197	200	172	146	110	95	45	23	22
Total Revenue	167	213	197	200	172	146	110	95	45	23	22
Operating Revenue	167	213	197	200	172	146	110	95	45	23	22
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	250	239	244	229	234	231	247	215	220	187	175
Selling, General & Admin Expense	129	121	122	128	130	142	146	111	102	84	78
Research & Development Expense	86	76	89	78	85	69	79	96	110	99	95
Other Operating Expenses / (Income)	34	41	34	23	20	20	22	8.38	7.81	-	0.00
Total Other Income / (Expense), net	-8.56	-9.90	-9.57	-8.10	-4.16	-2.64	-2.92	-1.40	-2.41	-3.12	-38
Interest Expense	11	12	13	9.36	6.97	7.40	7.31	7.34	7.53	7.74	7.90
Interest & Investment Income	2.66	3.40	2.89	3.18	3.30	4.55	4.99	6.00	5.39	4.58	2.81
Other Income / (Expense), net	-0.17	-1.77	0.07	-1.93	-0.50	0.22	-0.60	-0.06	-0.28	0.04	-33
Income Tax Expense	0.34	0.29	0.59	0.11	0.17	1.42	0.23	0.19	0.28	-1.47	0.45
Basic Earnings per Share	($0.74)	($0.30)	($0.46)	($0.30)	($0.54)	($0.70)	($1.17)	($1.02)	($1.56)	($1.52)	($1.75)
Weighted Average Basic Shares Outstanding	125.45M	123.91M	124.23M	123.90M	122.96M	118.68M	120.29M	119.32M	113.87M	106.11M	109.13M
Diluted Earnings per Share	($0.74)	($0.30)	($0.46)	($0.30)	($0.54)	($0.70)	($1.17)	($1.02)	($1.56)	($1.52)	($1.75)
Weighted Average Diluted Shares Outstanding	125.45M	123.91M	124.23M	123.90M	122.96M	118.68M	120.29M	119.32M	113.87M	106.11M	109.13M
Weighted Average Basic & Diluted Shares Outstanding	125.68M	125.52M	124.39M	121.77M	121.37M	120.58M	118.50M	117.74M	116.46M	111.29M	110.58M

This table details how cash moves in and out of Apellis Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	60	-201	-89	75	215	176	0.62	151	-11	22
Net Cash From Operating Activities	-88	-595	-514	-563	-160	-211	-131	-47	-26	-19
Net Cash From Continuing Operating Activities	-88	-595	-514	-563	-160	-211	-131	-47	-26	-19
Net Income / (Loss) Continuing Operations	-198	-529	-652	-746	-345	-305	-128	-51	-27	-47
Consolidated Net Income / (Loss)	-198	-529	-652	-746	-345	-305	-128	-51	-27	-47
Depreciation Expense	1.80	1.78	1.55	1.38	0.64	0.24	0.00	0.00	-	-
Amortization Expense	1.56	0.30	0.46	1.08	16	2.70	0.65	0.03	0.00	0.00
Non-Cash Adjustments To Reconcile Net Income	125	132	152	274	148	37	7.73	5.42	1.49	26
Changes in Operating Assets and Liabilities, net	-18	-200	-16	-94	20	53	-12	-1.03	-0.37	1.94
Net Cash From Investing Activities	-0.40	-0.67	60	248	-317	-1.69	0.00	0.00	0.00	0.00
Net Cash From Continuing Investing Activities	-0.40	-0.67	60	248	-317	-1.69	0.00	0.00	0.00	0.00
Purchase of Property, Plant & Equipment	-0.40	-0.77	-1.52	-1.10	-5.42	-1.69	0.00	0.00	-	-
Purchase of Investments	0.00	0.00	-332	-171	-879	0.00	0.00	-	-	-
Sale of Property, Plant & Equipment	0.00	0.10	0.00	0.00	-	-	-	-	-	-
Sale and/or Maturity of Investments	0.00	0.00	393	420	568	0.00	0.00	-	-	-
Net Cash From Financing Activities	149	394	366	392	692	389	132	197	15	41
Net Cash From Continuing Financing Activities	149	394	366	392	692	389	132	197	15	41
Repayment of Debt	-7.21	0.00	0.00	-	323	184	0.00	0.00	-	-
Issuance of Debt	365	0.00	0.00	-	-	-	-	26	0.00	0.00
Issuance of Common Equity	4.51	390	384	383	383	110	131	150	0.00	0.00
Other Financing Activities, net	-214	4.73	-19	8.90	-14	95	0.73	0.68	0.00	0.00
Effect of Exchange Rate Changes	-0.66	0.14	-0.49	-2.02	0.36	0.00	-0.04	0.00	0.00	-
Cash Interest Paid	29	3.29	5.00	10	13	0.99	1.82	0.13	0.00	-
Cash Income Taxes Paid	1.65	0.00	4.92	0.05	1.65	-	-	-	-	-

This table details how cash moves in and out of Apellis Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-53	14	37	34	-25	-101	-164	-149	213	-32	-20
Net Cash From Operating Activities	-53	19	34	-8.34	-133	-98	-169	-150	-178	-141	-154
Net Cash From Continuing Operating Activities	-53	19	34	-8.46	-133	-98	-169	-150	-178	-141	-154
Net Income / (Loss) Continuing Operations	-92	-36	-57	-38	-66	-89	-140	-122	-178	-166	-191
Consolidated Net Income / (Loss)	-92	-36	-57	-38	-66	-89	-140	-122	-178	-166	-191
Depreciation Expense	0.45	0.45	0.46	0.45	0.44	0.48	0.46	0.43	0.42	0.39	0.40
Amortization Expense	0.59	0.59	0.66	0.24	0.08	0.08	0.08	0.15	0.00	0.18	0.05
Non-Cash Adjustments To Reconcile Net Income	27	26	27	35	36	33	28	36	35	31	64
Changes in Operating Assets and Liabilities, net	10	28	63	-6.29	-103	-43	-58	-64	-36	-6.42	-28
Net Cash From Investing Activities	-0.01	-0.02	-	-0.09	-0.29	0.00	-0.05	-0.37	-0.26	124	125
Net Cash From Continuing Investing Activities	-0.01	-0.02	-	-0.09	-0.29	0.00	-0.05	-0.37	-0.26	124	125
Purchase of Property, Plant & Equipment	-0.01	-0.02	-	-0.09	-0.29	-0.10	-0.05	-0.37	-0.26	-0.85	-0.20
Purchase of Investments	0.00	-	-	-	0.00	-	-	-	0.00	-	-
Sale and/or Maturity of Investments	0.00	-	-	-	0.00	-	-	-	0.00	125	125
Net Cash From Financing Activities	0.27	-4.00	2.54	42	108	-3.91	5.75	1.56	391	-16	9.64
Net Cash From Continuing Financing Activities	0.27	-4.00	2.54	42	108	-3.91	5.75	1.56	391	-16	9.64
Issuance of Common Equity	0.00	1.32	-	3.19	0.00	1.62	-	3.75	384	1.71	-
Other Financing Activities, net	0.27	0.31	2.54	-325	108	-5.54	5.75	-2.19	6.72	-18	9.64
Effect of Exchange Rate Changes	0.36	-0.97	0.17	0.34	-0.21	0.58	-0.46	-0.05	0.06	0.19	-0.31
Cash Interest Paid	11	9.92	12	5.31	1.64	-	1.64	-	1.64	-	1.64
Cash Income Taxes Paid	0.14	1.05	0.60	-	0.00	-0.58	0.19	0.13	0.25	4.76	-

This table presents Apellis Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Total Assets	885	789	760	882	961	389	204	182	27
Total Current Assets	789	766	720	824	917	373	202	182	27
Cash & Equivalents	411	351	552	640	566	352	176	176	25
Restricted Cash	1.32	1.11	1.27	1.56	1.27	0.00	-	-	-
Accounts Receivable	265	206	7.73	10	0.00	-	-	-	-
Inventories, net	81	146	86	16	0.00	-	-	-	-
Prepaid Expenses	18	39	36	25	11	20	24	5.06	1.13
Other Current Assets	12	22	37	71	27	1.31	1.84	1.31	1.37
Plant, Property, & Equipment, net	2.95	4.35	6.15	6.18	6.80	1.66	0.98	0.00	0.00
Total Noncurrent Assets	93	18	35	52	37	14	0.12	0.12	0.06
Other Noncurrent Operating Assets	93	18	35	52	37	14	0.12	-	-
Total Liabilities & Shareholders' Equity	885	789	760	882	961	389	204	182	27
Total Liabilities	657	594	590	683	756	355	43	33	3.64
Total Current Liabilities	186	248	168	132	128	66	17	6.55	3.64
Accounts Payable	39	38	37	17	8.48	8.36	10	3.66	2.55
Accrued Expenses	140	128	95	103	112	55	5.10	2.89	1.09
Current Deferred Revenue	0.00	0.00	-	-	-	-	-	-	-
Other Current Liabilities	6.75	82	35	12	7.92	2.61	0.00	-	-
Total Noncurrent Liabilities	471	347	423	551	628	289	26	26	0.00
Long-Term Debt	453	93	93	189	359	143	25	26	0.00
Other Noncurrent Operating Liabilities	18	254	330	362	269	147	0.16	-	-
Commitments & Contingencies	0.00	0.00	-	-	0.00	0.00	-	-	-
Total Equity & Noncontrolling Interests	229	195	170	199	205	34	161	149	24
Total Preferred & Common Equity	229	195	170	199	205	34	161	149	24
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	92
Total Common Equity	229	195	170	199	205	34	161	149	-68
Common Stock	3,267	3,036	2,480	1,857	1,131	616	438	298	30
Retained Earnings	-3,035	-2,837	-2,309	-1,657	-926	-581	-277	-149	-98
Accumulated Other Comprehensive Income / (Loss)	-3.31	-3.54	-0.88	-2.09	-0.12	-0.15	-0.12	0.00	-

This table presents Apellis Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	807	902	904	832	818	916	979	873
Total Current Assets	728	834	860	811	797	893	954	832
Cash & Equivalents	358	397	360	326	452	616	765	584
Restricted Cash	1.43	1.37	1.34	1.10	1.09	1.09	1.28	1.26
Short-Term Investments	0.00	-	-	0.00	0.00	0.00	0.00	124
Accounts Receivable	235	279	304	268	169	111	32	8.09
Inventories, net	82	121	153	161	99	103	85	60
Prepaid Expenses	37	24	29	43	45	34	37	30
Other Current Assets	13	12	12	12	31	27	34	24
Plant, Property, & Equipment, net	2.51	3.38	3.84	4.20	4.79	5.34	5.97	5.68
Total Noncurrent Assets	77	65	41	16	17	18	19	35
Other Noncurrent Operating Assets	77	65	41	16	17	18	19	35
Total Liabilities & Shareholders' Equity	807	902	904	832	818	916	979	873
Total Liabilities	643	665	640	565	586	570	567	565
Total Current Liabilities	178	191	169	215	186	175	139	115
Accounts Payable	55	43	38	27	18	28	31	14
Accrued Expenses	116	140	123	101	117	98	71	80
Other Current Liabilities	6.94	6.79	6.21	84	50	50	36	22
Total Noncurrent Liabilities	465	473	471	350	400	395	428	450
Long-Term Debt	453	452	457	93	93	93	93	93
Other Noncurrent Operating Liabilities	11	21	14	257	307	302	335	357
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	164	237	264	267	232	345	412	307
Total Preferred & Common Equity	164	237	264	267	232	345	412	307
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	164	237	264	267	232	345	412	307
Common Stock	3,295	3,239	3,209	3,174	2,982	2,955	2,900	2,453
Retained Earnings	-3,128	-2,999	-2,942	-2,904	-2,749	-2,609	-2,487	-2,143
Accumulated Other Comprehensive Income / (Loss)	-3.05	-3.14	-3.36	-3.53	-1.07	-0.80	-0.78	-3.03

This table displays calculated financial ratios and metrics derived from Apellis Pharmaceuticals' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	97.02%	425.83%	13.31%	-73.44%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	67.86%	17.54%	14.40%	-142.88%	-0.26%	-135.74%	-150.17%	-86.66%	41.46%	0.00%
EBIT Growth	67.35%	17.47%	14.41%	-131.10%	-4.69%	-136.83%	-151.33%	-86.75%	41.46%	0.00%
NOPAT Growth	68.10%	13.03%	-10.88%	-150.92%	25.79%	-125.14%	-151.98%	-86.08%	41.42%	0.00%
Net Income Growth	62.57%	18.94%	12.62%	-116.41%	-13.18%	-138.98%	-149.97%	-88.04%	41.69%	0.00%
EPS Growth	64.04%	27.64%	30.43%	-92.59%	6.33%	-109.40%	36.41%	-14.29%	59.90%	0.00%
Operating Cash Flow Growth	85.23%	-15.76%	8.77%	-250.88%	23.99%	-60.88%	-181.66%	-79.19%	-37.90%	0.00%
Free Cash Flow Firm Growth	23.60%	-33.51%	-16.92%	-3,961.34%	36.82%	85.54%	-178.11%	-103.12%	0.00%	0.00%
Invested Capital Growth	515.10%	77.71%	7.62%	0.35%	-80.11%	-1,591.08%	6,549.17%	83.93%	0.00%	0.00%
Revenue Q/Q Growth	9.25%	45.34%	-33.28%	-74.03%	38,699.69%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	25.57%	13.44%	-3.19%	-48.59%	40.34%	-31.34%	-17.43%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	25.00%	13.38%	-3.19%	-46.91%	38.70%	-32.10%	-17.45%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	26.13%	13.33%	-14.36%	-69.30%	52.48%	-31.35%	-17.66%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	20.88%	12.77%	-2.85%	-43.49%	35.70%	-33.42%	-17.11%	0.00%	0.00%	0.00%
EPS Q/Q Growth	20.00%	15.56%	0.00%	-41.21%	38.47%	-30.67%	-58.11%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	57.16%	6.72%	-5.82%	-82.45%	58.26%	-21.66%	-28.30%	-23.90%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	22.01%	1.91%	-24.41%	-96.15%	95.34%	-667.47%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-7.68%	49.53%	6.22%	-4.95%	-16.95%	-13.89%	420.44%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-21.21%	-130.05%	-829.32%	-1,097.79%	-120.03%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-21.11%	-130.39%	-788.38%	-805.67%	-85.27%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-21.64%	-130.57%	-831.99%	-1,101.48%	-126.58%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-25.32%	-133.29%	-864.70%	-1,121.27%	-137.59%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.59%	100.40%	100.10%	100.05%	100.54%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	116.33%	101.67%	103.82%	101.75%	108.12%	100.55%	99.65%	100.19%	99.50%	99.89%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-113.21%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-37.99%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	19.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-93.55%	-290.14%	-353.93%	-370.20%	-288.86%	-312.20%	-82.28%	-59.06%	-114.00%	0.00%
Cash Return on Invested Capital (CROIC)	-167.06%	0.00%	0.00%	0.00%	0.00%	0.00%	-863.71%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-20.21%	-66.86%	-76.43%	-79.59%	-47.01%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-23.64%	-68.26%	-79.44%	-81.02%	-51.10%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-93.55%	-290.14%	-353.93%	-370.20%	-288.86%	-312.20%	-82.28%	-27.58%	327.03%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-86.58%	-271.76%	-383.92%	-375.69%	-168.60%	-890.20%	-79.21%	-34.25%	-114.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-115	-362	-416	-375	-150	-202	-90	-36	-19	-33
NOPAT Margin	-14.78%	-91.27%	-551.87%	-563.97%	-59.69%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-75.23%	-46.32%	-48.48%	-71.81%	-53.53%	-57.49%	-25.44%	-17.78%	-64.40%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-16.95%	-125.88%	-158.50%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	64.13%	126.28%	367.48%	265.57%	55.62%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	41.92%	89.36%	513.43%	519.61%	119.66%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	121.11%	230.39%	888.38%	905.67%	185.27%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-169	-518	-628	-733	-317	-303	-128	-51	-27	-47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-166	-516	-625	-731	-301	-300	-127	-51	-27	-47
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	17.37	36.47	33.66	20.78	21.18	57.15	4.61	7.33	0.00	0.00
Price to Tangible Book Value (P/TBV)	17.37	36.47	33.66	20.78	21.18	57.15	4.61	7.33	0.00	0.00
Price to Revenue (P/Rev)	5.08	17.89	75.81	62.01	17.28	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	14.92	0.00	0.00	0.00	0.00	0.00	50.44	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	5.13	17.23	69.71	54.30	15.21	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.98	0.48	0.55	0.95	1.75	4.17	0.17	0.18	0.00	0.00
Long-Term Debt to Equity	1.98	0.48	0.55	0.95	1.75	4.17	0.16	0.18	0.00	0.00
Financial Leverage	-0.52	-1.97	-2.64	-2.56	-3.06	-1.84	-0.96	-1.01	-1.05	0.00
Leverage Ratio	3.96	4.25	4.46	4.57	5.65	3.04	1.24	1.21	1.15	0.00
Compound Leverage Factor	4.60	4.32	4.63	4.65	6.11	3.05	1.24	1.22	1.15	0.00
Debt to Total Capital	66.46%	32.35%	35.31%	48.76%	63.69%	80.64%	14.38%	15.05%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.89%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	66.46%	32.35%	35.31%	48.76%	63.69%	80.64%	13.50%	15.05%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	386.88%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	33.54%	67.65%	64.69%	51.24%	36.31%	19.36%	85.62%	84.95%	-286.88%	0.00%
Debt to EBITDA	-2.73	-0.18	-0.15	-0.26	-1.19	-0.48	-0.21	-0.52	0.00	0.00
Net Debt to EBITDA	-0.24	0.50	0.74	0.70	1.73	0.70	1.17	2.93	0.00	0.00
Long-Term Debt to EBITDA	-2.73	-0.18	-0.15	-0.26	-1.19	-0.48	-0.20	-0.52	0.00	0.00
Debt to NOPAT	-3.92	-0.26	-0.22	-0.50	-2.40	-0.71	-0.30	-0.74	0.00	0.00
Net Debt to NOPAT	-0.35	0.72	1.11	1.37	3.48	1.04	1.67	4.20	0.00	0.00
Long-Term Debt to NOPAT	-3.92	-0.26	-0.22	-0.50	-2.40	-0.71	-0.28	-0.74	0.00	0.00
Altman Z-Score	-0.10	1.25	-0.19	-0.73	2.24	-0.41	7.57	18.83	0.00	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	53.29%	386.88%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.25	3.10	4.29	6.25	7.15	5.67	11.89	27.77	7.52	0.00
Quick Ratio	3.65	2.25	3.34	5.39	6.84	5.35	10.35	26.80	6.83	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-449	-588	-440	-376	-9.27	-15	-101	-36	-18	0.00
Operating Cash Flow to CapEx	-21,802.98%	-88,239.61%	-33,710.30%	-51,054.03%	-2,959.94%	-12,471.06%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-11.12	-19.87	-13.49	-28.43	-0.31	-2.16	-40.38	-97.37	0.00	0.00
Operating Cash Flow to Interest Expense	-2.18	-20.11	-15.75	-42.53	-5.36	-31.11	-52.22	-124.34	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-2.19	-20.13	-15.79	-42.61	-5.54	-31.36	-52.22	-124.34	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.93	0.51	0.09	0.07	0.37	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	3.32	3.70	8.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	214.16	75.59	12.24	10.26	59.27	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	110.10	98.55	43.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	110.10	98.55	43.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	269	-65	-290	-314	-316	-175	12	-0.18	-1.13	0.00
Invested Capital Turnover	7.66	-2.23	-0.25	-0.21	-1.02	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	334	226	24	1.10	-140	-187	12	0.95	-1.13	0.00
Enterprise Value (EV)	4,010	6,834	5,258	3,614	3,812	1,747	593	943	0.00	0.00
Market Capitalization	3,969	7,093	5,718	4,127	4,332	1,956	742	1,092	0.00	0.00
Book Value per Share	$1.84	$1.64	$1.54	$2.28	$2.70	$0.54	$2.86	$2.96	($8.10)	$0.00
Tangible Book Value per Share	$1.84	$1.64	$1.54	$2.28	$2.70	$0.54	$2.86	$2.96	($8.10)	$0.00
Total Capital	681	288	263	388	563	177	188	175	24	0.00
Total Debt	453	93	93	189	359	143	27	26	0.00	0.00
Total Long-Term Debt	453	93	93	189	359	143	25	26	0.00	0.00
Net Debt	40	-259	-460	-513	-520	-209	-149	-149	-25	0.00
Capital Expenditures (CapEx)	0.40	0.67	1.52	1.10	5.42	1.69	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	191	166	-1.16	-9.91	-90	-45	11	-0.18	-1.13	0.00
Debt-free Net Working Capital (DFNWC)	603	519	552	692	789	307	187	175	24	0.00
Net Working Capital (NWC)	603	519	552	692	789	307	185	175	24	0.00
Net Nonoperating Expense (NNE)	82	167	236	371	195	103	38	15	8.03	14
Net Nonoperating Obligations (NNO)	40	-259	-460	-513	-520	-209	-149	-149	-25	0.00
Total Depreciation and Amortization (D&A)	3.36	2.08	2.01	2.46	16	2.94	0.65	0.03	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	24.42%	41.97%	-1.54%	-14.89%	-35.93%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	77.23%	130.80%	731.77%	1,039.92%	314.73%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	77.23%	130.80%	731.77%	1,039.92%	314.73%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.60)	$0.00	($6.15)	($8.84)	($4.59)	($4.90)	($2.34)	($3.68)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	123.91M	0.00	106.11M	97.73M	80.38M	75.32M	56.28M	50.37M	0.00	0.00
Adjusted Diluted Earnings per Share	($1.60)	$0.00	($6.15)	($8.84)	($4.59)	($4.90)	($2.34)	($3.68)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	123.91M	0.00	106.11M	97.73M	80.38M	75.32M	56.28M	50.37M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($8.84)	($4.59)	($4.90)	($2.34)	($3.68)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	125.52M	0.00	111.29M	84.42M	75.16M	62.23M	54.40M	13.87M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-115	-362	-416	-375	-150	-202	-90	-36	-19	-33
Normalized NOPAT Margin	-14.78%	-91.27%	-551.87%	-563.97%	-59.69%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-25.18%	-132.76%	-863.81%	-1,120.75%	-136.86%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.19	-17.51	-19.23	-55.37	-10.60	-44.66	-50.92	-135.85	0.00	0.00
NOPAT to Interest Expense	-2.86	-12.24	-12.76	-28.35	-5.00	-29.71	-35.63	-94.83	0.00	0.00
EBIT Less CapEx to Interest Expense	-4.20	-17.53	-19.28	-55.46	-10.78	-44.90	-50.92	-135.85	0.00	0.00
NOPAT Less CapEx to Interest Expense	-2.87	-12.26	-12.80	-28.43	-5.18	-29.96	-35.63	-94.83	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.01%	0.00%	0.00%	-0.20%

This table displays calculated financial ratios and metrics derived from Apellis Pharmaceuticals' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-3.21%	45.19%	78.29%	110.26%	284.26%	545.89%	400.54%	481.85%	211.84%	-62.41%	290.37%
EBITDA Growth	-32.85%	67.88%	66.39%	74.42%	64.52%	48.76%	25.98%	18.96%	-35.84%	-13.44%	4.01%
EBIT Growth	-33.40%	66.87%	65.71%	73.97%	64.31%	48.60%	25.87%	18.84%	-35.64%	-13.42%	3.98%
NOPAT Growth	-34.21%	69.04%	65.51%	75.55%	64.54%	48.48%	10.37%	18.96%	-35.73%	-83.50%	-19.49%
Net Income Growth	-38.85%	58.96%	59.04%	69.14%	62.64%	46.64%	26.68%	21.76%	-27.96%	-12.21%	2.20%
EPS Growth	-37.04%	57.14%	60.68%	70.59%	65.38%	53.95%	33.14%	30.14%	-9.86%	0.00%	23.25%
Operating Cash Flow Growth	59.84%	119.78%	120.17%	94.45%	25.13%	30.46%	-9.50%	-40.30%	-59.21%	-25.11%	8.43%
Free Cash Flow Firm Growth	16.07%	-23.50%	-63.11%	-137.62%	-91.21%	-105.25%	-186.25%	-82.18%	-183.63%	-117.95%	-62.03%
Invested Capital Growth	686.99%	515.10%	326.96%	301.11%	112.53%	77.71%	58.59%	45.79%	17.13%	7.62%	-3.39%
Revenue Q/Q Growth	-21.52%	7.97%	-1.43%	15.88%	17.73%	32.59%	16.25%	111.77%	97.88%	2.75%	35.13%
EBITDA Q/Q Growth	-206.56%	41.65%	-50.24%	50.57%	25.88%	38.93%	-14.35%	31.44%	-6.80%	11.78%	-25.20%
EBIT Q/Q Growth	-198.93%	40.84%	-50.50%	49.88%	25.76%	38.77%	-14.26%	31.28%	-6.73%	11.69%	-25.09%
NOPAT Q/Q Growth	-218.46%	44.66%	-60.58%	52.58%	26.54%	38.34%	-13.82%	31.21%	-6.72%	-7.27%	-2.90%
Net Income Q/Q Growth	-153.69%	36.72%	-52.55%	43.31%	25.01%	36.84%	-14.91%	31.35%	-7.10%	13.22%	-22.63%
EPS Q/Q Growth	-146.67%	34.78%	-53.33%	44.44%	22.86%	40.17%	-14.71%	34.62%	-2.63%	13.14%	-19.86%
Operating Cash Flow Q/Q Growth	-375.88%	-43.22%	508.87%	93.73%	-35.87%	42.11%	-12.61%	15.46%	-26.20%	8.85%	-44.28%
Free Cash Flow Firm Q/Q Growth	19.45%	22.25%	19.17%	-65.79%	-18.52%	-2.69%	-17.76%	-33.41%	-27.22%	-43.22%	25.05%
Invested Capital Q/Q Growth	-4.07%	-7.68%	-19.16%	999.28%	150.60%	49.53%	28.36%	31.51%	10.00%	6.22%	6.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-49.43%	-12.66%	-23.42%	-15.36%	-36.02%	-57.22%	-124.23%	-126.29%	-390.09%	-721.20%	-840.03%
Operating Margin	-49.96%	-12.31%	-24.02%	-14.74%	-36.03%	-57.74%	-124.17%	-126.82%	-390.41%	-723.88%	-693.41%
EBIT Margin	-50.06%	-13.14%	-23.99%	-15.71%	-36.32%	-57.59%	-124.71%	-126.89%	-391.03%	-723.70%	-842.08%
Profit (Net Income) Margin	-55.29%	-17.11%	-29.19%	-18.86%	-38.55%	-60.51%	-127.03%	-128.50%	-396.42%	-732.43%	-867.20%
Tax Burden Percent	100.37%	100.79%	101.04%	100.30%	100.26%	101.63%	100.17%	100.16%	100.16%	99.12%	100.23%
Interest Burden Percent	110.05%	129.13%	120.43%	119.69%	105.85%	103.38%	101.69%	101.11%	101.22%	102.10%	102.74%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-186.75%	-66.02%	-147.69%	-71.69%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-138.44%	-49.55%	-131.80%	-63.74%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	45.08%	25.65%	86.07%	44.81%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-141.66%	-40.36%	-61.62%	-26.88%	-122.94%	-290.14%	-224.59%	-193.31%	-158.06%	-353.93%	-507.11%
Cash Return on Invested Capital (CROIC)	-244.63%	-167.06%	-197.76%	-210.59%	-1,761.58%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-47.38%	-12.27%	-19.95%	-10.85%	-21.02%	-29.49%	-40.25%	-24.42%	-38.97%	-66.48%	-136.13%
Return on Assets (ROA)	-52.34%	-15.97%	-24.27%	-13.03%	-22.31%	-30.99%	-40.99%	-24.73%	-39.51%	-67.29%	-140.19%
Return on Common Equity (ROCE)	-141.66%	-40.36%	-61.62%	-26.88%	-122.94%	-290.14%	-224.59%	-193.31%	-158.06%	-353.93%	-507.11%
Return on Equity Simple (ROE_SIMPLE)	-136.21%	0.00%	-105.47%	-125.94%	-156.47%	0.00%	-260.92%	-190.23%	-167.67%	0.00%	-206.27%
Net Operating Profit after Tax (NOPAT)	-58	-18	-33	-21	-43	-59	-96	-84	-123	-115	-107
NOPAT Margin	-34.97%	-8.62%	-16.81%	-10.32%	-25.22%	-40.42%	-86.92%	-88.78%	-273.29%	-506.72%	-485.39%
Net Nonoperating Expense Percent (NNEP)	-48.31%	-16.47%	-15.89%	-7.95%	-5.06%	-8.18%	-9.06%	-6.35%	-7.61%	-10.51%	-19.60%
Return On Investment Capital (ROIC_SIMPLE)	-9.44%	-2.69%	-	-	-	-20.57%	-	-	-	-43.73%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	77.55%	57.16%	61.97%	64.14%	75.15%	96.81%	131.93%	117.27%	227.65%	372.27%	355.49%
R&D to Revenue	51.81%	35.93%	45.00%	39.04%	49.15%	47.33%	71.94%	100.73%	245.34%	438.70%	431.66%
Operating Expenses to Revenue	149.96%	112.31%	124.02%	114.74%	136.03%	157.74%	224.17%	226.82%	490.41%	823.88%	793.41%
Earnings before Interest and Taxes (EBIT)	-83	-28	-47	-31	-63	-84	-138	-121	-175	-164	-186
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-82	-27	-46	-31	-62	-84	-137	-120	-175	-163	-185
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	16.72	17.37	14.81	17.61	26.58	36.47	19.28	30.72	17.81	33.66	24.41
Price to Tangible Book Value (P/TBV)	16.72	17.37	14.81	17.61	26.58	36.47	19.28	30.72	17.81	33.66	24.41
Price to Revenue (P/Rev)	3.54	5.08	4.91	7.40	13.52	17.89	16.41	57.49	69.33	75.81	66.38
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	11.01	14.92	12.25	13.19	209.22	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	3.66	5.13	4.99	7.56	13.08	17.23	15.09	54.65	62.97	69.71	60.92
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.76	1.98	1.91	1.73	0.35	0.48	0.40	0.27	0.23	0.55	0.30
Long-Term Debt to Equity	2.76	1.98	1.91	1.73	0.35	0.48	0.40	0.27	0.23	0.55	0.30
Financial Leverage	-0.33	-0.52	-0.65	-0.70	-1.34	-1.97	-1.81	-1.75	-1.66	-2.64	-3.44
Leverage Ratio	3.80	3.96	3.66	2.99	2.67	4.25	3.13	2.82	2.43	4.46	5.59
Compound Leverage Factor	4.19	5.11	4.41	3.57	2.82	4.39	3.19	2.85	2.46	4.55	5.75
Debt to Total Capital	73.41%	66.46%	65.60%	63.37%	25.88%	32.35%	28.58%	21.19%	18.38%	35.31%	23.16%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	73.41%	66.46%	65.60%	63.37%	25.88%	32.35%	28.58%	21.19%	18.38%	35.31%	23.16%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	26.59%	33.54%	34.40%	36.63%	74.12%	67.65%	71.42%	78.81%	81.62%	64.69%	76.84%
Debt to EBITDA	-2.44	-2.73	-2.03	-1.46	-0.23	-0.18	-0.16	-0.14	-0.14	-0.15	-0.15
Net Debt to EBITDA	-0.50	-0.24	-0.24	-0.31	0.58	0.50	0.61	0.81	1.00	0.74	1.02
Long-Term Debt to EBITDA	-2.44	-2.73	-2.03	-1.46	-0.23	-0.18	-0.16	-0.14	-0.14	-0.15	-0.15
Debt to NOPAT	-3.48	-3.92	-2.89	-2.09	-0.33	-0.26	-0.22	-0.22	-0.21	-0.22	-0.25
Net Debt to NOPAT	-0.72	-0.35	-0.35	-0.44	0.83	0.72	0.86	1.22	1.50	1.11	1.70
Long-Term Debt to NOPAT	-3.48	-3.92	-2.89	-2.09	-0.33	-0.26	-0.22	-0.22	-0.21	-0.22	-0.25
Altman Z-Score	-1.43	0.42	-0.01	1.31	3.88	3.07	0.56	7.88	4.73	1.82	4.94
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.08	4.25	4.36	5.08	3.77	3.10	4.29	5.11	6.88	4.29	7.21
Quick Ratio	3.33	3.65	3.53	3.93	2.76	2.25	3.35	4.16	5.75	3.34	6.21
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-283	-352	-452	-560	-338	-285	-277	-236	-177	-139	-97
Operating Cash Flow to CapEx	-667,625.00%	96,800.00%	0.00%	-9,265.56%	-45,386.69%	-103,026.32%	-359,755.32%	-40,364.25%	-68,579.15%	-16,538.66%	-78,784.18%
Free Cash Flow to Firm to Interest Expense	-25.65	-30.51	-36.11	-59.81	-48.46	-38.49	-37.95	-32.09	-23.45	-17.94	-12.26
Operating Cash Flow to Interest Expense	-4.83	1.68	2.72	-0.89	-19.09	-13.22	-23.13	-20.45	-23.59	-18.19	-19.54
Operating Cash Flow Less CapEx to Interest Expense	-4.83	1.68	2.72	-0.90	-19.13	-13.24	-23.14	-20.51	-23.63	-18.30	-19.56
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.95	0.93	0.83	0.69	0.58	0.51	0.32	0.19	0.10	0.09	0.16
Accounts Receivable Turnover	3.08	3.32	3.19	3.03	3.50	3.70	3.08	3.12	5.60	8.46	19.47
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	231.28	214.16	175.11	137.07	103.14	75.59	52.12	32.86	17.86	12.24	18.55
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	118.34	110.10	114.38	120.55	104.24	98.55	118.61	117.13	65.21	43.14	18.75
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	118.34	110.10	114.38	120.55	104.24	98.55	118.61	117.13	65.21	43.14	18.75
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	258	269	291	360	33	-65	-128	-179	-261	-290	-310
Invested Capital Turnover	5.34	7.66	8.78	6.95	-4.58	-2.23	-1.25	-0.72	-0.37	-0.25	-0.37
Increase / (Decrease) in Invested Capital	225	334	419	539	294	226	181	151	54	24	-10
Enterprise Value (EV)	2,839	4,010	3,566	4,751	6,854	6,834	4,118	10,085	6,667	5,258	6,887
Market Capitalization	2,745	3,969	3,512	4,656	7,088	7,093	4,479	10,609	7,341	5,718	7,504
Book Value per Share	$1.31	$1.84	$1.95	$2.18	$2.21	$1.64	$1.97	$2.97	$3.70	$1.54	$2.80
Tangible Book Value per Share	$1.31	$1.84	$1.95	$2.18	$2.21	$1.64	$1.97	$2.97	$3.70	$1.54	$2.80
Total Capital	618	681	689	722	360	288	325	438	505	263	400
Total Debt	453	453	452	457	93	93	93	93	93	93	93
Total Long-Term Debt	453	453	452	457	93	93	93	93	93	93	93
Net Debt	94	40	54	96	-234	-259	-361	-524	-674	-460	-617
Capital Expenditures (CapEx)	0.01	0.02	0.00	0.09	0.29	0.10	0.05	0.37	0.26	0.85	0.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	190	191	244	329	269	166	158	101	49	-1.16	6.68
Debt-free Net Working Capital (DFNWC)	549	603	643	691	596	519	611	718	816	552	716
Net Working Capital (NWC)	549	603	643	691	596	519	611	718	816	552	716
Net Nonoperating Expense (NNE)	34	18	24	17	23	29	44	38	55	51	84
Net Nonoperating Obligations (NNO)	94	40	54	96	-234	-259	-361	-524	-674	-460	-617
Total Depreciation and Amortization (D&A)	1.04	1.03	1.12	0.69	0.52	0.55	0.54	0.57	0.42	0.57	0.45
Debt-free, Cash-free Net Working Capital to Revenue	24.43%	24.42%	34.17%	52.38%	51.35%	41.97%	57.77%	54.46%	46.51%	-1.54%	5.91%
Debt-free Net Working Capital to Revenue	70.81%	77.23%	89.85%	109.86%	113.75%	130.80%	223.96%	389.01%	770.27%	731.77%	633.79%
Net Working Capital to Revenue	70.81%	77.23%	89.85%	109.86%	113.75%	130.80%	223.96%	389.01%	770.27%	731.77%	633.79%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.74)	($0.30)	($0.46)	($0.30)	($0.54)	($0.70)	($1.17)	($1.02)	($1.56)	($1.52)	($1.75)
Adjusted Weighted Average Basic Shares Outstanding	125.45M	123.91M	124.23M	123.90M	122.96M	118.68M	120.29M	119.32M	113.87M	106.11M	109.13M
Adjusted Diluted Earnings per Share	($0.74)	($0.30)	($0.46)	($0.30)	($0.54)	($0.70)	($1.17)	($1.02)	($1.56)	($1.52)	($1.75)
Adjusted Weighted Average Diluted Shares Outstanding	125.45M	123.91M	124.23M	123.90M	122.96M	118.68M	120.29M	119.32M	113.87M	106.11M	109.13M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	125.68M	125.52M	124.39M	121.77M	121.37M	120.58M	118.50M	117.74M	116.46M	111.29M	110.58M
Normalized Net Operating Profit after Tax (NOPAT)	-58	-18	-33	-21	-43	-59	-96	-84	-123	-115	-107
Normalized NOPAT Margin	-34.97%	-8.62%	-16.81%	-10.32%	-25.22%	-40.42%	-86.92%	-88.78%	-273.29%	-506.72%	-485.39%
Pre Tax Income Margin	-55.09%	-16.97%	-28.88%	-18.80%	-38.45%	-59.54%	-126.82%	-128.30%	-395.79%	-738.92%	-865.18%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-7.56	-2.42	-3.77	-3.35	-8.98	-11.39	-18.83	-16.42	-23.29	-21.20	-23.50
NOPAT to Interest Expense	-5.28	-1.59	-2.64	-2.20	-6.24	-7.99	-13.13	-11.48	-16.28	-14.84	-13.55
EBIT Less CapEx to Interest Expense	-7.56	-2.42	-3.77	-3.36	-9.03	-11.40	-18.84	-16.47	-23.33	-21.31	-23.53
NOPAT Less CapEx to Interest Expense	-5.28	-1.59	-2.64	-2.21	-6.28	-8.01	-13.13	-11.54	-16.31	-14.95	-13.57
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Apellis Pharmaceuticals' Financials

When does Apellis Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Apellis Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Apellis Pharmaceuticals' net income changed over the last 9 years?

Apellis Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$197.88 million in 2024, rising from -$46.52 million in 2015. The previous period was -$528.63 million in 2023. Find out what analysts predict for Apellis Pharmaceuticals in the coming months.

What is Apellis Pharmaceuticals's operating income?

Apellis Pharmaceuticals's total operating income in 2024 was -$164.98 million, based on the following breakdown:

Total Gross Profit: $781.37 million
Total Operating Expenses: $946.35 million

How has Apellis Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Apellis Pharmaceuticals' total revenue changed from $0.00 in 2015 to $781.37 million in 2024, a change of 78,136,700,000.0%.

How much debt does Apellis Pharmaceuticals have?

Apellis Pharmaceuticals' total liabilities were at $656.51 million at the end of 2024, a 10.5% increase from 2023, and a 17,941.3% increase since 2016.

How much cash does Apellis Pharmaceuticals have?

In the past 8 years, Apellis Pharmaceuticals' cash and equivalents has ranged from $24.86 million in 2016 to $640.19 million in 2021, and is currently $411.29 million as of their latest financial filing in 2024.

How has Apellis Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Apellis Pharmaceuticals' book value per share changed from 0.00 in 2015 to 1.84 in 2024, a change of 183.7%.

Related Companies

This page (NASDAQ:APLS) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apellis Pharmaceuticals (APLS) Financials

Frequently Asked Questions About Apellis Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apellis Pharmaceuticals (APLS) Financials

Annual Income Statements for Apellis Pharmaceuticals

Quarterly Income Statements for Apellis Pharmaceuticals

Annual Cash Flow Statements for Apellis Pharmaceuticals

Quarterly Cash Flow Statements for Apellis Pharmaceuticals

Annual Balance Sheets for Apellis Pharmaceuticals

Quarterly Balance Sheets for Apellis Pharmaceuticals

Annual Metrics And Ratios for Apellis Pharmaceuticals

Quarterly Metrics And Ratios for Apellis Pharmaceuticals

Frequently Asked Questions About Apellis Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools